ACAAI 2019

Complete Coverage

Using Electronic Health Records to Predict Mortality Post COPD Hospitalization

By

Sheila Jacobs

Publish Date May 9, 2022

For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?

Omalizumab Reduces Asthma Exacerbations Across Airway Reversibility Subgroups

By

Brandon May

Publish Date November 22, 2019

Treatment with omalizumab may reduce exacerbations of asthma in patients in several different airway reversibility subgroups.

Worsening of Disease Common in Asthma Prior to Biologic Therapy Initiation

By

Britt Gambino

Publish Date November 22, 2019

Patients who began biologic treatment for asthma tended to have more progressive worsening of disease in the previous 2 years

Benralizumab Does Not Cause Changes in Weight, Blood Pressure in Severe Asthma

By

Brandon May

Publish Date November 22, 2019

Benralizumab does not induce changes in weight or blood pressure when administered for up to 1 year in patients with severe asthma.

Mometasone Furoate-Formoterol Improves Lung Function in Pediatric Asthma

By

Britt Gambino

Publish Date November 22, 2019

The addition of formoterol to mometasone furoate was well tolerated and provided significant improvement in lung function in children compared with mometasone furoate alone.

Benralizumab Associated With Improvements in SGRQ Scores in Asthma

By

Pulmonology Advisor Contributing Writer

Publish Date November 22, 2019

In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.

Omalizumab Response Similar Across Number, Type of Allergens in Allergic Asthma

By

Britt Gambino

Publish Date November 22, 2019

Response to omalizumab was similar regardless of the number and type of sensitizing allergens in patients with allergic asthma.

Dupilumab May Lower Exacerbation Rates in Allergic Bronchopulmonary Aspergillosis

By

Britt Gambino

Publish Date November 13, 2019

In a post hoc analysis of the LIBERTY ASTHMA QUEST study, researchers found that dupilumab may reduce exacerbations in patients with allergic bronchopulmonary aspergillosis.

Benralizumab Improved Total Nasal Symptom Score in Severe Asthma

By

Pulmonology Advisor Contributing Writer

Publish Date November 11, 2019

Among patients with severe asthma, benralizumab treatment improved nasal symptoms, which worsen with increasing baseline blood eosinophil count.

Mepolizumab Significantly Reduces Asthma Exacerbations and Associated Costs

By

Pulmonology Advisor Contributing Writer

Publish Date November 11, 2019

In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.